Clinical Trials
51 trialsEpcoritamab and Rituximab for First-line Follicular Lymphoma
Dana-Farber Cancer Institute
TAB
University of Cincinnati
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
REFRACT
University of Birmingham
FEAD
Helse Stavanger HF
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
University of Washington
Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma
Evopoint Biosciences Inc.
A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
University of Miami
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
University of Washington
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Beth Israel Deaconess Medical Center
Odronextamab in Low Tumor Volume Advanced FL
Beth Israel Deaconess Medical Center
5HTP Regulation Of Asthma In Children
Indiana University
NEO100 and High-Grade Meningioma
Neonc Technologies, Inc.
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
SOUNDTRACK-B
AstraZeneca
SCARF-1
Karolinska Institutet
Epco, Zanu, Ritux for R/R FL or MZL
Dana-Farber Cancer Institute
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
H. Lee Moffitt Cancer Center and Research Institute
AQUAx2
MeiraGTx UK II Ltd
FIL_MOZART
Fondazione Italiana Linfomi - ETS
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Sun Yat-sen University
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Brown University
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Massachusetts General Hospital
Auto Stem Cell Transplant for Lymphoma Patients
Masonic Cancer Center, University of Minnesota
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Hope Biosciences Research Foundation
Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
City of Hope Medical Center
HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL
Masonic Cancer Center, University of Minnesota
O-ICE
New York Medical College
Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use Disorders
Medical University of South Carolina
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
Zanubrutinib Combined With G-CVP in Previously Untreated FL
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
University of California, Davis
PSI_CUD
McMaster University
Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL
The First Affiliated Hospital of Xiamen University
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Radiotherapy Followed by Tiselizumab Combined With RCHOP in Previously Untreated Bulky Follicular Lymphoma
Tianjin Medical University Cancer Institute and Hospital
Zanubrutinib in Combination With Obinutuzumab (ZO) for Newly Diagnosed Follicular Lymphoma
The First Affiliated Hospital of Xiamen University
Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL
Australasian Leukaemia and Lymphoma Group
Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma
Chinese PLA General Hospital